Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Retinal Biologics market size was valued at USD 14413.0 million in 2022 and is expected to expand at a CAGR of 12.36% during the forecast period, reaching USD 28995.83 million by 2028.
Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Retinal biologics refer to bioengineered molecules which are implanted inside the eyes in order to heal chronic retinal diseases.
Licensing and cooperation agreements between major players to expand product coverage
Many companies are signing licensing and cooperation agreements to expand their products to countries around the world to meet unmet demand. For example, in August 2021, Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
In order to improve the R&D pipeline portfolio, many companies have signed cooperation agreements with various other companies and universities, which are expected to promote the development of the retinal biologics market during the forecast period.
Side effects and disadvantages of retinal biologics
When retinal biologics is used to treat retinal diseases, it may produce certain side effects, which will bring challenges to its market development. Serious side effects of retinal biologics may lead to eye infection, permanent decline of vision, increase of intraocular pressure, formation or deterioration of cataract, etc. The most common side effects are red eyes, cataract, eye swelling, irritation or pain.
The economic burden of drug development for enterprises is heavy
The economic burden of the development of retinal biologics is heavy. Therefore, many companies are generally not interested in the research and development of retinal biologics. The market participants of retinal biologics are mainly concentrated in Europe and the United States, which is mainly due to the support policies of developed countries for the development of retinal biologics. Overseas policies mainly include fee reduction and exemption, financial support, R & D assistance, priority review, market exclusivity, etc., which has greatly stimulated the enthusiasm of pharmaceutical enterprises to develop retinal biologics. However, this factor will also bring challenges to its market development.
Region Overview:
In 2022, the share of the Retinal Biologics market in North America stood at 50.65%.
Company Overview:
Regeneron Pharmaceuticals, Inc is one of the major players operating in the Retinal Biologics market, holding a share of 37.8% in 2023.
Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
Bayer
Bayer is a company focusing on seeds, crop protection, and non-agricultural pest control. It develops genetically modified crops and pesticides. Bayer serves customers worldwide.
Segmentation Overview:
As for product types, the Macular Degeneration segment held the largest market share in 2022.
Macular Degeneration
Macular degeneration is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. The current treatment for macular degeneration is the injection of anti-VEGF medication into each affected eye. Three anti-VEGF biologics are currently available: the VEGF-decoy aflibercept (Eylea), antibody fragments ranibizumab (Lucentis), and brolucizumab (Beovu).
Diabetic Retinopathy
Diabetic retinopathy usually only requires specific treatment when it reaches an advanced stage and there's a risk to patients' vision. In some cases of diabetic maculopathy, injections of a medicine called anti-VEGF may be given directly into patients' eyes to prevent new blood vessels forming at the back of the eyes.
Diabetic Macular Edema
Diabetic macular edema (DME) is one of the main causes of visual impairment in persons with diabetic retinopathy. Owing to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Besides ranibizumab and aflibercept, bevacizumab demonstrated efficacy in the treatment of DME.
Uveitis
Uveitis is characterized by intraocular inflammation affecting the uveal structures of the eye, including the iris, ciliary body, and choroid. The success in rheumatology of the TNF-α inhibitors adalimumab (ADA) and infliximab (IFX) over the past several years has led to their use in uveitis.
Application Overview:
The market's largest segment by application is the segment Hospitals, with a market share of 68.01% in 2022.
This report elaborates on the market size, market characteristics, and market growth of the Retinal Biologics industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Retinal Biologics. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Retinal Biologics Market Report Include:
Market Size Estimates: Retinal Biologics market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Retinal Biologics market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Retinal Biologics market
Segment Market Analysis: Retinal Biologics market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Retinal Biologics market situations and prospects in major and top regions and countries
Retinal Biologics Market
Retinal Biologics Industry Chain: Retinal Biologics market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Retinal Biologics Industry News, Policies by regions
Retinal Biologics Industry Porters Five Forces Analysis
Key players in the global Retinal Biologics market are covered in Chapter 2:
AbbVie Inc
Roche
Regeneron Pharmaceuticals, Inc
Bayer
Novartis
Amgen Inc
Johnson & Johnson Services, Inc
In Chapter 6 and Chapter 9, on the basis of types, the Retinal Biologics market from 2018 to 2028 is primarily split into:
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
In Chapter 7 and Chapter 10, on the basis of applications, the Retinal Biologics market from 2018 to 2028 covers:
Hospitals
Clinics
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Retinal Biologics market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Retinal Biologics industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Retinal Biologics market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Retinal Biologics industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Retinal Biologics market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Retinal Biologics market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Retinal Biologics market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Retinal biologics refer to bioengineered molecules which are implanted inside the eyes in order to heal chronic retinal diseases.
Licensing and cooperation agreements between major players to expand product coverage
Many companies are signing licensing and cooperation agreements to expand their products to countries around the world to meet unmet demand. For example, in August 2021, Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
In order to improve the R&D pipeline portfolio, many companies have signed cooperation agreements with various other companies and universities, which are expected to promote the development of the retinal biologics market during the forecast period.
Side effects and disadvantages of retinal biologics
When retinal biologics is used to treat retinal diseases, it may produce certain side effects, which will bring challenges to its market development. Serious side effects of retinal biologics may lead to eye infection, permanent decline of vision, increase of intraocular pressure, formation or deterioration of cataract, etc. The most common side effects are red eyes, cataract, eye swelling, irritation or pain.
The economic burden of drug development for enterprises is heavy
The economic burden of the development of retinal biologics is heavy. Therefore, many companies are generally not interested in the research and development of retinal biologics. The market participants of retinal biologics are mainly concentrated in Europe and the United States, which is mainly due to the support policies of developed countries for the development of retinal biologics. Overseas policies mainly include fee reduction and exemption, financial support, R & D assistance, priority review, market exclusivity, etc., which has greatly stimulated the enthusiasm of pharmaceutical enterprises to develop retinal biologics. However, this factor will also bring challenges to its market development.
Region Overview:
In 2022, the share of the Retinal Biologics market in North America stood at 50.65%.
Company Overview:
Regeneron Pharmaceuticals, Inc is one of the major players operating in the Retinal Biologics market, holding a share of 37.8% in 2023.
Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
Bayer
Bayer is a company focusing on seeds, crop protection, and non-agricultural pest control. It develops genetically modified crops and pesticides. Bayer serves customers worldwide.
Segmentation Overview:
As for product types, the Macular Degeneration segment held the largest market share in 2022.
Macular Degeneration
Macular degeneration is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. The current treatment for macular degeneration is the injection of anti-VEGF medication into each affected eye. Three anti-VEGF biologics are currently available: the VEGF-decoy aflibercept (Eylea), antibody fragments ranibizumab (Lucentis), and brolucizumab (Beovu).
Diabetic Retinopathy
Diabetic retinopathy usually only requires specific treatment when it reaches an advanced stage and there's a risk to patients' vision. In some cases of diabetic maculopathy, injections of a medicine called anti-VEGF may be given directly into patients' eyes to prevent new blood vessels forming at the back of the eyes.
Diabetic Macular Edema
Diabetic macular edema (DME) is one of the main causes of visual impairment in persons with diabetic retinopathy. Owing to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Besides ranibizumab and aflibercept, bevacizumab demonstrated efficacy in the treatment of DME.
Uveitis
Uveitis is characterized by intraocular inflammation affecting the uveal structures of the eye, including the iris, ciliary body, and choroid. The success in rheumatology of the TNF-α inhibitors adalimumab (ADA) and infliximab (IFX) over the past several years has led to their use in uveitis.
Application Overview:
The market's largest segment by application is the segment Hospitals, with a market share of 68.01% in 2022.
This report elaborates on the market size, market characteristics, and market growth of the Retinal Biologics industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Retinal Biologics. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Retinal Biologics Market Report Include:
Market Size Estimates: Retinal Biologics market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Retinal Biologics market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Retinal Biologics market
Segment Market Analysis: Retinal Biologics market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Retinal Biologics market situations and prospects in major and top regions and countries
Retinal Biologics Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Retinal Biologics Industry Chain: Retinal Biologics market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Retinal Biologics Industry News, Policies by regions
Retinal Biologics Industry Porters Five Forces Analysis
Key players in the global Retinal Biologics market are covered in Chapter 2:
AbbVie Inc
Roche
Regeneron Pharmaceuticals, Inc
Bayer
Novartis
Amgen Inc
Johnson & Johnson Services, Inc
In Chapter 6 and Chapter 9, on the basis of types, the Retinal Biologics market from 2018 to 2028 is primarily split into:
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
In Chapter 7 and Chapter 10, on the basis of applications, the Retinal Biologics market from 2018 to 2028 covers:
Hospitals
Clinics
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Retinal Biologics market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Retinal Biologics industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Retinal Biologics market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Retinal Biologics industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Retinal Biologics market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Retinal Biologics market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Retinal Biologics market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
